Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie


Sign up for our daily newsletter


Stock rises for AcelRX as pain management drug device succeeds in late-stage study

May 21, 2013 8:12 am by | 0 Comments

(Reuters) - AcelRX Pharmaceuticals Inc said its experimental drug device to treat post-operative pain met the main goal of controlling pain in a late-stage study among patients who had undergone knee or hip replacement surgery.

Shares of the company rose 31 percent to $8.44 in trading before the bell.

The device showed that the drug showed a decrease in pain intensity as measured on a clinical scale, compared to a placebo.

The study is the last of the three late-stage trials of the Sufentanil NanoTab PCA System, which allows patients to dose themselves with painkiller tablets.

Advertisement

The therapy had shown in the two earlier late-stage trials that it was at least as effective as the standard of care in treating post-operative pain and was significantly better than a placebo.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
0 comments